Values are mean + SEM. (n=5 per group). aP<0.0001 and abP<0.05 significantly higher from the diabetic group treated with levcromakalim. D: diabetic group LevD : potassium channel activated diabetic group LevDG : potassium channel activated diabetic group treated with glibenclamide LevDM: potassium channel activated diabetic group treated with metformin LevDI20/40 : potassium channel activated diabetic group treated with insulin

Figure 2: The effect of levcromakalim treatment on the creatinine clearance of streptozotocin-induced rats treated with glibenclamide, metformin and insulin.